U.S. Software Stock News

NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Intel’s Fab 34 Buyback Tightens AI Foundry Control And Balance Sheet Risk

Intel (NasdaqGS:INTC) is buying back Apollo Global Management’s 49% stake in its Fab 34 facility in Ireland. The transaction is valued at $14.2b and restores Intel to full ownership of the advanced chip plant. Fab 34 is central to Intel’s plans for advanced AI processors and contract manufacturing for external customers. For you as an investor, this move sits at the intersection of Intel’s core business in CPUs, its push into AI chips, and its foundry services ambitions. The company has...
NasdaqCM:CELH
NasdaqCM:CELHBeverage

The Bull Case For Celsius Holdings (CELH) Could Change Following Deutsche Bank’s Upgrade And Margin Outlook

In recent weeks, Celsius Holdings reported quarterly revenue of US$721.63 million and earnings per share of US$0.26, both beating analyst estimates, while Deutsche Bank upgraded its rating after reassessing competition from Costco’s private-label energy drink and the company’s integration of Alani Nu and Rockstar. Together with Celsius’s roughly 20% share of U.S. energy drink dollars and expectations for gross margin recovery to the low 50s by mid-2026, these developments highlight how brand...
NYSE:KGS
NYSE:KGSEnergy Services

Assessing Kodiak Gas Services (KGS) Valuation After A Strong 3-Month Share Price Run

Why Kodiak Gas Services is on investors’ radar Kodiak Gas Services (KGS) has drawn attention after a strong past 3 months, with the stock showing a 54.8% total return while operating a US focused contract compression and services business. See our latest analysis for Kodiak Gas Services. That recent 54.8% 3 month share price return contrasts with a softer 7 day share price return of a 2.1% decline. The latest close at $57.90 sits against a 1 year total shareholder return of 57.3%, suggesting...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate

Eli Lilly (NYSE:LLY) received U.S. FDA approval for Foundayo, its first oral, once-daily GLP-1 weight loss pill for obesity and overweight patients with related conditions. The company launched Foundayo commercially in the U.S. immediately after approval, making it available through LillyDirect and retail pharmacies. Foundayo can be taken at any time without food or water restrictions and is being introduced with tailored pricing to broaden access. Eli Lilly enters a new phase in obesity...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Why Moderna (MRNA) Is Down 6.6% After Its ‘Moderna 2.0’ Cancer-Vaccine Pivot - And What's Next

In late March 2026, Moderna participated in the World Vaccine Congress Washington and the 4th annual Entrepreneurship Summit, where senior leaders highlighted its evolving mRNA vaccine and cancer-therapy ambitions while the company continued to address operational and legal challenges. Together with a multi‑billion‑dollar patent settlement and progress toward individualized cancer vaccines, these events underline Moderna’s attempt to reset its long‑term direction beyond COVID‑19. Next,...
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

Assessing Snap (SNAP) Valuation As Activist Investors Push For Major Changes

Snap (SNAP) is back in the spotlight after activist investors Irenic Capital Management and Randian Capital publicly pressed for sweeping changes, including a potential Spectacles spin off, tighter costs, and a sharper focus on artificial intelligence. See our latest analysis for Snap. The recent activist letters arrived after a long stretch of weak performance, with the share price at US$4.90 and a year-to-date share price return of about 40% in decline. The 1-year total shareholder return...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

A Look At C.H. Robinson (CHRW) Valuation After New Diesel Cost Relief Measures

C.H. Robinson Worldwide (CHRW) has responded to higher diesel costs tied to a new Middle East conflict by rolling out free discount fuel cards and temporary fee free cash advances for its contract carriers. See our latest analysis for C.H. Robinson Worldwide. The latest diesel support measures arrive at a time when C.H. Robinson’s share price has been volatile, with a 1-day share price return of 1.46%, a 30-day share price return of 10.01%, and a 1-year total shareholder return of 66.99%...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Is It Time To Revisit Varonis Systems (VRNS) After Steep Share Price Declines?

If you are wondering whether Varonis Systems at around US$21.74 is starting to look interesting on price, the key question is how that tag compares with what the business might reasonably be worth. The stock has seen mixed returns, with a 1.6% move over the last 7 days, a 5.8% decline over 30 days, and much steeper negative returns of 32.1% year to date and 47.7% over the past year. These moves have kept Varonis on many watchlists as investors reassess their appetite for higher risk software...
NasdaqGS:PSKY
NasdaqGS:PSKYMedia

Paramount Skydance Warner Bros Deal Raises Scale And Debt Questions

Paramount Skydance (NasdaqGS:PSKY) has won a high profile bidding war to acquire Warner Bros. Discovery in a historic media merger. The deal creates one of the largest combined film, TV, and streaming groups, but leaves the company with a substantially elevated post deal debt load. Industry commentary is widely critical of the high leverage, with some questioning whether the transaction could threaten Paramount Skydance’s future viability. The acquisition is subject to an extended Department...
NasdaqCM:NKTR
NasdaqCM:NKTRPharmaceuticals

Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run

Company overview and recent stock performance Nektar Therapeutics (NKTR) has drawn fresh attention after an extended run in its share price, with the stock showing strong returns over the past 3 months and the past year. For context, Nektar is a US based biopharmaceutical company focused on immunotherapy, with a pipeline that includes rezpegaldesleukin in Phase 2b for autoimmune and inflammatory diseases, plus several earlier stage candidates targeting autoimmune and fibrotic conditions, as...
NasdaqGS:NXPI
NasdaqGS:NXPISemiconductor

Is NXP’s Peridio Edge AI Partnership Quietly Reframing Its Platform Strategy for NXPI Investors?

Peridio recently announced it has joined the NXP Semiconductors Partner Program as a Registered Partner, deepening their collaboration around Avocado OS and NXP’s i.MX processors and Ara discrete neural processing units for edge AI devices. This move highlights how NXP’s edge AI hardware is increasingly being paired with production-grade software infrastructure, positioning its platforms as a turnkey option for manufacturers facing tighter cybersecurity and regulatory requirements. We’ll now...
NYSE:PHR
NYSE:PHRHealthcare Services

Phreesia (PHR) Is Down 25.5% After Cutting 2027 Revenue Outlook Amid Pharma Spend Uncertainty – Has The Bull Case Changed?

In late March 2026, Phreesia, Inc. reported fourth-quarter and full-year results showing higher revenue and a swing to GAAP profitability, while also cutting its fiscal 2027 revenue outlook to US$510 million–US$520 million amid reduced visibility into pharmaceutical client spending. The company simultaneously filed a US$34.61 million shelf registration for 3,033,251 common shares tied to an ESOP-related offering, highlighting ongoing use of equity-based compensation even as management guides...
NYSE:DIS
NYSE:DISEntertainment

How Disneyland Paris’ World of Frozen Opening Will Impact Walt Disney (DIS) Investors

In late March 2026, Disneyland Paris opened its World of Frozen expansion and reintroduced its second gate as Disney Adventure World, a multibillion‑dollar immersive upgrade anchored by new attractions, a central lake, and a nighttime spectacular. This expansion, alongside Disney’s broader parks and streaming push, highlights how the company is leaning on experiential IP to reinforce its position as a global tourism and media powerhouse. With Disney’s largest‑ever Disneyland Paris expansion...
NYSE:BMY
NYSE:BMYPharmaceuticals

Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions

Janux Therapeutics has nominated a tumor activated cancer therapeutic using its TRACTr platform in partnership with Bristol Myers Squibb, triggering a $35 million milestone payment. Bristol Myers Squibb is expanding its "Standing in the Gaap" multiple myeloma care survey, aiming to better understand and address equity gaps in treatment. NYSE:BMY is adding fresh R&D momentum through its collaboration with Janux, as the new tumor activated candidate moves closer to potential clinical...
NYSE:RLI
NYSE:RLIInsurance

Will RLI’s New Claims Leadership Deepen Its Underwriting Edge And Profit Story (RLI)?

RLI Corp. recently promoted Cory Figiel to Chief Claim Officer and elevated Charles Spiekerman to Vice President, Claim, while its Transportation division partnered with Transportation Advisors to offer policyholders discounted, AI-enabled compliance and safety services for commercial fleets. These leadership moves and the transportation compliance partnership come shortly after RLI reported a quarter where earnings outpaced expectations but book value per share lagged analyst estimates,...
NasdaqGS:LFUS
NasdaqGS:LFUSElectronic

What Littelfuse (LFUS)'s Iran Energy Shock Exposure Test Means For Shareholders

In late March 2026, Littelfuse, a provider of electronic components, was caught up in market volatility after President Trump threatened to target Iran’s critical Kharg Island energy hub, which handles most of the country’s crude exports, raising fears of a severe energy supply shock. While this geopolitical escalation sparked a flight to safety and broader concerns about inflation and economic risk, analysts indicated it did not alter their view of Littelfuse’s core business outlook. We’ll...
NYSE:ALB
NYSE:ALBChemicals

Albemarle (ALB) Valuation Revisited After Mixed Q4 And Growing Institutional Support

Why Albemarle stock is back in focus Albemarle (ALB) is back on many watchlists after a mixed fourth quarter, where earnings fell short of expectations but revenue came in ahead. This has prompted investors to reassess the stock’s risk and reward trade off. See our latest analysis for Albemarle. Recent moves in Albemarle’s share price tell a mixed story, with a 26.18% 90 day share price return and a very large 1 year total shareholder return of 151.35%. The 3 year total shareholder return is...
NYSE:LRN
NYSE:LRNConsumer Services

A Fresh Look At Stride (LRN) Valuation After Recent Share Price Momentum

Why Stride (LRN) Is Drawing Fresh Attention Stride (LRN) is back on many investors’ radar after a period of mixed share performance, with a strong past 3 months contrasted by weaker 1 year returns and solid multi year gains. This recent share price pattern, together with current profitability metrics and value score data, is prompting closer scrutiny of how the online education provider’s business mix and earnings profile might align with different investment goals. See our latest analysis...
NasdaqGS:MNDY
NasdaqGS:MNDYSoftware

Lawsuit Tests monday.com Growth Story AI Spending And Revenue Targets

A securities fraud class action lawsuit has been filed against monday.com (NasdaqGS:MNDY). The suit alleges that the company made materially false and misleading statements about its business. Key issues cited include slowing customer growth, inadequate AI investments, and rescinded revenue targets. monday.com operates as a work management and collaboration platform, serving teams that want to centralize projects, workflows, and data. The lawsuit arrives at a time when software companies...
NasdaqGS:MDLN
NasdaqGS:MDLNMedical Equipment

Medline Awards And Vendor Win Highlight Growth And Valuation Opportunity

Medline (NasdaqGS:MDLN) has received two healthcare supply chain awards from a leading industry collaborative, recognizing its supplier relationships and resilience. The company has also entered a new prime vendor agreement with an established senior living provider, expanding its presence in that segment. For investors tracking NasdaqGS:MDLN, these developments arrive with the shares at $44.0 and a year to date return of 8.3%. The stock has seen a 3.1% gain over the past week alongside a...
BATS:CBOE
BATS:CBOECapital Markets

Cboe CNBC Deal Puts Options Data And Education In The Spotlight

Cboe Global Markets and CNBC have agreed to a multi year collaboration to air daily live options market coverage from Cboe's Chicago trading floor. Live programming is scheduled to begin on April 6, featuring real time options activity and analysis supported by proprietary Cboe data. The partnership will include a dedicated CNBC options beat reporter and plans for a permanent broadcast studio on the trading floor. Cboe Global Markets (BATS:CBOE), recently trading at $280.29, has seen a...
NasdaqGS:QS
NasdaqGS:QSAuto Components

Is QS Options Frenzy Reframing QuantumScape’s Solid-State Battery Story Around Risk Rather Than Earnings?

In recent days, QuantumScape has experienced a jump in options trading activity as investors focus on its efforts to develop next-generation solid-state lithium-metal batteries for electric vehicles. This renewed interest comes even as the company continues to report negative earnings and has seen insider selling, highlighting a tension between enthusiasm for its technology roadmap and questions around its financial trajectory. We’ll now examine how this surge in options trading interest...
NasdaqGS:ULTA
NasdaqGS:ULTASpecialty Retail

How Ulta Beauty’s New Strategy and Growth Chief Could Reframe ULTA’s Long-Term Playbook

In March 2026, Ulta Beauty elevated Kristin Wolf to the newly created role of Chief Strategy & Growth Officer, expanding her remit across corporate strategy, international expansion, new growth segments, and AI integration. This leadership move ties together Ulta’s recent pushes into marketplace offerings, wellness, and social commerce, potentially reshaping how the retailer prioritizes growth initiatives and innovation execution. Next, we’ll examine how Wolf’s expanded growth and AI remit...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

NANO Nuclear Energy (NNE) Is Down 7.0% After KRONOS Microreactor Construction Permit Filing Milestone

NANO Nuclear Energy Inc. recently announced that its partner, the Grainger College of Engineering at the University of Illinois Urbana-Champaign, submitted a Construction Permit Application to the U.S. Nuclear Regulatory Commission for the KRONOS MMR microreactor, marking a key step toward potential construction and licensing on the university’s campus. This move places NANO Nuclear among a small group of advanced reactor developers that have progressed to full CPA submission, signaling that...